Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
54
DERM Quote, Financials, Valuation and Earnings
Last price:
$8.41
Seasonality move
:
6.26%
Day range:
$8.05 - $8.49
52-week range:
$4.85 - $9.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.30x
P/B ratio:
10.81x
Volume:
73.7K
Avg. volume:
119.7K
1-year change:
63.81%
Market cap:
$280M
Revenue:
$56.1M
EPS (TTM):
-$0.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DERM
Journey Medical Corp.
|
$18.9M | -- | 55.42% | -- | $13.50 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.4M | $0.63 | 11.8% | 33.07% | $88.87 |
|
FBIO
Fortress Biotech, Inc.
|
$26.2M | -$0.31 | 73.08% | -72.5% | $10.75 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DERM
Journey Medical Corp.
|
$8.42 | $13.50 | $280M | -- | $0.00 | 0% | 3.30x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.20 | $31.21 | $3.9B | 14.93x | $0.00 | 0% | 3.73x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.68 | $457.00 | $44.1B | 147.39x | $0.00 | 0% | 11.96x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$61.83 | $88.87 | $11.9B | 23.17x | $0.00 | 0% | 3.92x |
|
FBIO
Fortress Biotech, Inc.
|
$3.45 | $10.75 | $107.1M | -- | $0.00 | 0% | 1.62x |
|
SVRA
Savara, Inc.
|
$5.59 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DERM
Journey Medical Corp.
|
49.42% | -1.153 | 13.47% | 1.08x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
FBIO
Fortress Biotech, Inc.
|
55.01% | 0.810 | 55.12% | 1.93x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DERM
Journey Medical Corp.
|
$10.8M | -$1.5M | -19.67% | -44.34% | -8.67% | -$2.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
FBIO
Fortress Biotech, Inc.
|
$10.7M | -$6.8M | -56.09% | -223.06% | -38.63% | -$6.1M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Journey Medical Corp. vs. Competitors
-
Which has Higher Returns DERM or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of 25.76%. Journey Medical Corp.'s return on equity of -44.34% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About DERM or ACAD?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 60.33%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 34.53%. Given that Journey Medical Corp. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Journey Medical Corp. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is DERM or ACAD More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock DERM or ACAD?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or ACAD?
Journey Medical Corp. quarterly revenues are $17.6M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Journey Medical Corp.'s net income of -$2.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.30x versus 3.73x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.30x -- $17.6M -$2.3M ACADACADIA Pharmaceuticals, Inc.3.73x 14.93x $278.6M $71.8M
-
Which has Higher Returns DERM or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of 16.99%. Journey Medical Corp.'s return on equity of -44.34% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About DERM or ALNY?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 60.33%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.37%. Given that Journey Medical Corp. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Journey Medical Corp. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is DERM or ALNY More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock DERM or ALNY?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or ALNY?
Journey Medical Corp. quarterly revenues are $17.6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Journey Medical Corp.'s net income of -$2.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.30x versus 11.96x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.30x -- $17.6M -$2.3M ALNYAlnylam Pharmaceuticals, Inc.11.96x 147.39x $1.1B $186.4M
-
Which has Higher Returns DERM or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of -3.91%. Journey Medical Corp.'s return on equity of -44.34% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About DERM or BMRN?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 60.33%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 43.73%. Given that Journey Medical Corp. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Journey Medical Corp. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is DERM or BMRN More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock DERM or BMRN?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or BMRN?
Journey Medical Corp. quarterly revenues are $17.6M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Journey Medical Corp.'s net income of -$2.3M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.30x versus 3.92x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.30x -- $17.6M -$2.3M BMRNBioMarin Pharmaceutical, Inc.3.92x 23.17x $786.8M -$30.7M
-
Which has Higher Returns DERM or FBIO?
Fortress Biotech, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of 50.07%. Journey Medical Corp.'s return on equity of -44.34% beat Fortress Biotech, Inc.'s return on equity of -223.06%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M FBIOFortress Biotech, Inc.60.8% $0.11 $133.5M -
What do Analysts Say About DERM or FBIO?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 60.33%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 211.59%. Given that Fortress Biotech, Inc. has higher upside potential than Journey Medical Corp., analysts believe Fortress Biotech, Inc. is more attractive than Journey Medical Corp..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 FBIOFortress Biotech, Inc.2 0 0 -
Is DERM or FBIO More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.433, suggesting its more volatile than the S&P 500 by 43.28%.
-
Which is a Better Dividend Stock DERM or FBIO?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DERM or FBIO?
Journey Medical Corp. quarterly revenues are $17.6M, which are smaller than Fortress Biotech, Inc. quarterly revenues of $17.6M. Journey Medical Corp.'s net income of -$2.3M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.30x versus 1.62x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.30x -- $17.6M -$2.3M FBIOFortress Biotech, Inc.1.62x -- $17.6M $8.8M
-
Which has Higher Returns DERM or SVRA?
Savara, Inc. has a net margin of -13.13% compared to Journey Medical Corp.'s net margin of --. Journey Medical Corp.'s return on equity of -44.34% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical Corp.61.32% -$0.09 $51.2M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About DERM or SVRA?
Journey Medical Corp. has a consensus price target of $13.50, signalling upside risk potential of 60.33%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 93.43%. Given that Savara, Inc. has higher upside potential than Journey Medical Corp., analysts believe Savara, Inc. is more attractive than Journey Medical Corp..
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical Corp.4 0 0 SVRASavara, Inc.6 0 0 -
Is DERM or SVRA More Risky?
Journey Medical Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock DERM or SVRA?
Journey Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical Corp. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or SVRA?
Journey Medical Corp. quarterly revenues are $17.6M, which are larger than Savara, Inc. quarterly revenues of --. Journey Medical Corp.'s net income of -$2.3M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Journey Medical Corp.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical Corp. is 3.30x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical Corp.3.30x -- $17.6M -$2.3M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 21.1% over the past day.
Buy
90
TCMD alert for Feb 19
Tactile Systems Technology, Inc. [TCMD] is up 17.83% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 17.31% over the past day.
